N/A N=152 Post Market Surveillance Study of the Wingspan Stent System
Intracranial Atherosclerosis
Primary: Rate of Stroke or Death Among Participants — 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=229 A Randomized Controlled Trial of PCIT-ED for Preschool Depression
Depressive Disorder, Major
Primary: Kiddie Schedule for Affective Disorders and Schizophrenia - Early Childhood (KSADS-EC) MDD Core Symptom Score — 1.74; 4.15 number of symptoms (0-9)
Phase 2 N=130 A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
Migraine
Primary: Number of Participants With Headache Response at Two Hours After Initiation of Infusion of Study Drug — 23; 2; 10; 11 Participants — p=1.0000
Phase 4 N=189 Differentiating Unipolar and Bipolar Depression in Young Adults Using fMRI
Bipolar Disorder · Major Depression
Primary: HAM-D 17 Item: Hamilton Depression Rating Scale — 6.6; 4.91; 2.333; 3.75 score on a scale
N/A N=40 The Pick Two to Stick To Habit Development Intervention
Metabolic Syndrome
Primary: Self-reported Behavioral Automaticity Index — 10.4 score on a scale
Phase 1 N=44 A Study of Lasmiditan and Propranolol in Healthy Participants
Healthy
Primary: Change From Baseline (Day 8) in Mean Hourly Heart Rate Following Propranolol Administered Alone and When Coadministered With Lasmiditan — 59.7; 54.2 beats per minute (bpm)
Phase 3 N=266 Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Phase 1 N=42 Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
Migraine
Primary: Pharmacodynamics- Change From Pre-dose to 24 Hours in Vital Signs: Systolic Blood Pressure — 0.6; -2.3; -0.1 millimeters of mercury (mmHg)
N/A N=44 A Randomized Controlled Trial of Permanent vs Absorbable Suture for Uterosacral Ligament Suspension
Pelvic Organ Prolapse · Cystocele · Uterine Prolapse
Primary: Pelvic Organ Prolapse Quantification Exam (POP-Q) Point C — -7.25; -7 cm
N/A N=1,499 The Pharmacist Follows You and Your Medication From Hospital to Your Daily Life and Investigate What This Means to You
Cross-Sectional Study
Primary: Readmissions — 111; 98; 68 Participants
Phase 4 N=130 High vs Low Dose Dexamethasone on Complications in the Immediate Postoperative Phase After Mastectomy
Dexamethasone · Glucocorticoids · Mastectomy
Primary: Transfer to Post-anesthesia Care Unit (PACU) — 23; 23 Participants — p=1
Phase 1 N=15 An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients
Parkinson Disease
Primary: Safety and Tolerability Based on the Safety Variables (Adverse Events, Clinical Safety Laboratory Tests, Vital Signs, Weight, and ECG) — 0; 0; 2; 7 Participants
Phase 1 N=36 A Study of Lasmiditan in Healthy Elderly Participants
Healthy
Primary: Pharmacodynamics: Change From Baseline in Peak Hourly Mean Values of Systolic Blood Pressure (SBP) — 15.79; 15.50; 17.14 millimeters of mercury (mmHg) — p=<0.0001
Phase 4 N=138 Incontinence & Intimate Partners: Assessing the Contribution of Treatment
Urge Urinary Incontinence
Primary: Baseline Sexual Satisfaction Between Matched Female and Male Partners — 4.2; 4.8 score on a scale — p=.16
N/A N=50 nSTRIDE APS in Females With Primary Patellofemoral Osteoarthritis
Patellofemoral Osteoarthritis
Primary: Pain Measured With Knee Injury and Osteoarthritis Outcome Score (KOOS) Questionnaire Subscale Pain at 1, 3, 6 and 12 Months — 40.3; 53.5; 52.5; 54.9 score on a scale